Equibles does not estimate personal net worth.
Get an email with a short summary when Rigel Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get RIGL alertsRigel Pharmaceuticals Inc reported in an 8-K filed July 1, 2026 that Alison L. Hannah, M.D. resigned as member of the Board of Directors, effective July 1, 2026. Rigel Pharmaceuticals Inc reported in an 8-K filed July 1, 2026 that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026. Alison L. Hannah, M.D. has spoken on 2 earnings calls across 1 company, most recently for Rigel Pharmaceuticals Inc on November 5, 2026. Rigel Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rigel Pharmaceuticals Inc includes Raul R. Rodriguez (CEO and Board Member), Raul Rodriguez (CEO and Board Member), Dean Schorno (CFO) and 7 others.
“In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.”
“On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.”
“On slide 19, you can see our three hematology and oncology focus areas, R289, our dual IRAC1 and IV inhibitor, is currently under evaluation in a Phase 1b study for patients with relapsed or refractory, lower-risk MDS, and I am pleased that we will present updated data from the study in an oral session at ASH in…”
“I'm very excited to join Rigel at this important stage in the company's evolution.”
SEC 8-K
2026-07-01–present
Biotechnology · Healthcare
